Cyclacel Pharmaceuticalsの空売り状況は、投資家がCyclacel Pharmaceuticalsの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

Cyclacel Pharmaceuticals (NASDAQ:CYCCP) 株価情報, 空売り情報

Cyclacel Pharmaceuticals

Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company that develops targeted medicines for cancer and other proliferative diseases. The company develops several families of anticancer drugs that act on the cell cycle, including CDK (cyclin-dependent kinase) inhibitors and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib and plogosertib.

Cyclacel Pharmaceuticals, Inc. - 6% Convertible Preferred Stock

Cyclacel Pharmaceuticals Inc

CYCCP

Trading Halt: Halt status updated at 9:00:00 AM ET: Quotation Resumption: News and Resumption Times

Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending

Cyclacel Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCC#NASDAQ">CYCC</a>, NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCCP#NASDAQ">CYCCP</a>, "Cyclacel" or the "Company"))) today announced that it entered into an Exchange Agreement with FITTERS Diversified Berhad (9318.KL; "FITTERS"), an investment holding company engaged, through its subsidiaries, in the business of the sale of fire safety materials, equipment and fire prevention systems, "Waste-To-Resource" services and real estate development and construction.
Pursuant to the Exchange Agreement, all of the ordinary shares of FITTERS' subsidiary, Fitters Sdn. Bhd., a Malaysia-based private limited company ("Fitters Sub") shall be exchanged for common stock, par value $0.001, of Cyclacel (the "Purchaser Stock"), and Fitters Sub shall be continuing as a wholly-owned subsidiary of Cyclacel (the "Transaction"). As part of the Transaction, Cyclacel shall issue an amount of Purchaser Stock equal to 19.99% percent, which percentage may be subject to adjustment, of the issued and outstanding shares of Purchaser Stock as of the closing date to FITTERS. At the closing, it is expected that Cyclacel stockholders will own approximately 80.01% of the combined company.

News

CYCC

Cyclacel Pharmaceuticals Enters Exchange Agreement To Make FITTERS' Subsidiary, Fitters Sdn. Bhd., Its Wholly-Owned subsidiary

Cyclacel Pharmaceuticals, Inc. ("Cyclacel") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCC#NASDAQ">CYCC</a>, NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCCP#NASDAQ">CYCCP</a>), a biopharmaceutical company that develops innovative cancer medicines, today announced a change in control and leadership on February 26, 2025.
Pursuant to the closing of a Securities Purchase Agreement (the "Agreement") between Cyclacel's former interim chief executive officer David Lazar ("Seller") and Datuk Dr. Doris Wong Sing Ee ("Purchaser"), executed on February 11, 2025, Purchaser purchased from Seller, 1,000,000 shares of Series C Convertible Preferred Stock of Cyclacel, $0.0001 par value per share (the "Series C") and such number of the 2,100,000 shares of Series D Convertible Preferred Stock of Cyclacel, $0.0001 par value per share (the "Series D") held by Seller so that Purchaser owns 70% of the issued and outstanding shares of Cyclacel, which resulted in the issuance of 1,745,262 shares of Series D (collectively, the Series C and Series D, the "Securities"). The transaction contemplated by the Agreement closed on February 26, 2025 (the "Closing Date") at which point Purchaser purchased and succeeded to all of Seller's rights and interests under the securities purchase agreement between Seller and Cyclacel dated January 2, 2025.
Purchaser acquired the Securities for a total consideration of $6,300,000 (the "Purchase Price") less a holdback amount of $100,000 (the "Holdback Amount") to the escrow agent. The Purchase Price included a cash brokerage fee of $800,000. The Holdback Amount will be held by Purchaser for 120 days from the Closing Date to satisfy any indemnity and other agreed upon claims and expenses.
On the Closing Date, Seller issued written notice to Cyclacel to exercise the conversion rights related to the Series C and Series D shares into the common stock, par value $0.001 per share (the "Common Stock") of Cyclacel registered in Purchaser's name, as follows: (i) 1,000,000 shares of Series C into 2,650,000 shares of Common Stock and (ii) 1,745,262 shares of Series D into 191,978,820 shares of Common Stock. As of the Closing Date, Purchaser has become the new controlling shareholder of Cyclacel.
At the same time, David Lazar resigned as interim chief executive officer and secretary and Datuk Dr. Doris Wong Sing Ee was elected as Chief Executive Officer and Executive Director of Cyclacel. Cyclacel also announced the appointment of Kiu Cu Seng as Executive Director, Secretary and Chief Financial Officer and, in such role, he will serve as the Company's co-principal financial officer and co-principal accounting officer along with David Lazar until the effective date of his resignation on the earlier of the filing date of the Company's annual report on Form 10-K for the fiscal year ended December 31, 2024 or March 31, 2025.

Management

Cyclacel Pharmaceuticals Announces Leadership Change After $6.3M Share Purchase; Datuk Dr. Doris Wong Sing Ee Acquires 70% Stake And Becomes CEO; David Lazar Resigns As Interim CEO, Kiu Cu Seng Appointed CFO

Cyclacel Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCC#NASDAQ">CYCC</a>, NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCCP#NASDAQ">CYCCP</a>, ", Cyclacel", or the ", Company", ))), a biopharmaceutical company developing innovative cancer medicines, today announced that it is in the process of exploring and reviewing strategic alternatives on an expedited basis in order to preserve the Company's cash, including a potential transaction with investor David Lazar of Activist Investing, LLC, which transaction would be subject to the consent of an existing securityholder.
The Company's Board of Directors is reviewing a range of appropriate strategies to realize value from its assets. The Board has directed management to reduce operating costs while such alternatives are being explored. There can be no assurance that the exploration of strategic alternatives will result in any agreement or transaction, or as to the timing of any such agreement or transaction. Further, there can be no assurance that the Company will be able to reach an agreement, or consummate a transaction, with Mr. Lazar or receive the required consent of an existing securityholder to any such transaction.
As previously disclosed, the Company does not presently meet the continued listing requirements of the Nasdaq Stock Market and its securities would be subject to delisting if the Company fails to regain compliance during the required compliance period. In the event that the Company is not able to enter into a strategic transaction and/or secure additional funding, it may be forced to cease all business operations. In such event, the Company's stockholders may lose a part or all of their investment in the Company.

Cyclacel Pharmaceuticals Announces Its Exploration Of Potential Strategic Alternatives On An Expedited Basis In Order To Preserve The Company's Cash, Including A Potential Transaction With Investor David Lazar Of Activist Investing, LLC

Cyclacel Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCC#NASDAQ">CYCC</a>, NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCCP#NASDAQ">CYCCP</a>, ", Cyclacel", or the ", Company", ))), a biopharmaceutical company developing innovative cancer medicines, today announced that it has entered into a definitive agreement for the exercise of certain existing warrants to purchase an aggregate of 4,968,945 shares of its common stock having an original exercise price of $1.36 per share, originally issued in May 2024, at a reduced exercise price of $0.415 per share. The resale of the shares of common stock issuable upon exercise of the existing warrants is registered pursuant to an effective registration statement on Form S-1 (File No. 333-279157).
H.C. Wainwright &amp; Co. is acting as the exclusive placement agent for the offering.

Offerings

Cyclacel Pharmaceuticals Announces Exercise Of Warrants For $2.1M, Has Entered Into A Definitive Agreement For The Exercise Of Certain Existing Warrants To Purchase An Aggregate Of 4,968,945 Shares Of Its Common Stock Having An Original Exercise Price Of $1.36 Per Share, Originally Issued In May 2024, At A Reduced Exercise Price Of $0.415 Per Share

WIIM

Cyclacel Pharmaceuticals shares are trading higher after the company reported better-than-expected Q3 financial results.

Cyclacel Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCC#NASDAQ">CYCC</a>, NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCCP#NASDAQ">CYCCP</a>, ", Cyclacel", or the ", Company", )))), a biopharmaceutical company developing innovative cancer medicines, today announced that initial safety and efficacy data from twelve patients with advanced solid tumors enrolled in the Phase 2 part of the 065-101 clinical study of fadraciclib as a single agent will be presented as a poster at the 2024 AACR-NCI-EORTC 36th Symposium on Molecular Targets and Cancer Therapeutics ("Triple Meeting"), to be held in Barcelona, Spain (October 23-25, 2024). The patients were enrolled in the biomarker-enriched, Cohort 8 of the proof of concept study and were preselected for CDKN2A and/or CDKN2B abnormalities.
Details of the presentation are listed below:
<figure class="table"> 
<table>
<tbody>
<tr>
<td>Title:</td>
<td><a href="https://cm.eortc.org/cmPortal/Searchable/ena2024/config/Normal#!sessiondetails/0000110740_0">Fadraciclib, an oral CDK2/9 inhibitor, in patients with advanced solid tumors and lymphoma with CDKN2A and/or CDKN2B genetic alterations</a></td>
</tr>
<tr>
<td>Abstract Number:</td>
<td>59</td>
</tr>
<tr>
<td>Session:</td>
<td>Molecular Targeted Agents</td>
</tr>
<tr>
<td>Date/Time:</td>
<td>12:00 p.m. – 7:00 p.m. CEST on Wednesday, October 23, 2024</td>
</tr>
</tbody>
</table>
</figure>

Biotech

General

Cyclacel Pharmaceuticals To Present New Clinical Data From Phase 2 Study Of Oral Fadraciclib At The 2024 EORTC-NCI-AACR Symposium

<h3>Gainers</h3>
<ul>
<li>Cue Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CUE#NASDAQ">CUE</a>) shares rose 25.6% to $1.03 during Friday's regular session. The company's market cap stands at $61.9 million. </li>
<li>Capricor Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPR#NASDAQ">CAPR</a>) stock moved upwards by 23.66% to $21.11. The market value of their outstanding shares is at $745.9 million. </li>
<li>Entero Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENTO#NASDAQ">ENTO</a>) stock increased by 19.94% to $0.42. The company's market cap stands at $1.3 million. </li>
<li>HCW Biologics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCWB#NASDAQ">HCWB</a>) shares increased by 19.31% to $0.53. The company's market cap stands at $19.8 million. </li>
<li>AEON Biopharma (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/AEON#AMEX">AEON</a>) stock increased by 17.11% to $1.3. The company's market cap stands at $51.3 million. </li>
<li>IO Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IOBT#NASDAQ">IOBT</a>) shares increased by 15.84% to $1.17. The market value of their outstanding shares is at $77.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Impact BioMedical (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/IBO#AMEX">IBO</a>) shares fell 19.4% to $1.33 during Friday's regular session. The company's market cap stands at $15.2 million. </li>
<li>Avinger (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGR#NASDAQ">AVGR</a>) shares fell 18.59% to $1.05. The company's market cap stands at $2.2 million. </li>
<li>Renovaro (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RENB#NASDAQ">RENB</a>) stock decreased by 12.17% to $0.44. The company's market cap stands at $67.8 million. </li>
<li>LogicMark (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGMK#NASDAQ">LGMK</a>) shares fell 12.04% to $0.12. The market value of their outstanding shares is at $1.4 million. </li>
<li>Cyclacel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCCP#NASDAQ">CYCCP</a>) stock declined by 10.77% to $6.05. </li>
<li>Kezar Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KZR#NASDAQ">KZR</a>) stock decreased by 9.11% to $0.75. The company's market cap stands at $54.7 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

AEON

AVGR

CAPR

ENTO

HCWB

IOBT

LGMK

RENB

12 Health Care Stocks Moving In Friday's Intraday Session

&nbsp;- Novel CDK2/9 inhibitor fadraciclib induces anaphase catastrophe, a novel cancer-specific&nbsp;mechanism of action -
BERKELEY HEIGHTS, N.J., June 04, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCC#NASDAQ">CYCC</a>, NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCCP#NASDAQ">CYCCP</a>, "Cyclacel" or the "Company")))), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced a presentation by independent investigators of preclinical data demonstrating therapeutic potential of fadraciclib, the Company's cyclin-dependent kinase (CDK) 2/9 inhibitor, as a novel treatment for metastatic colorectal cancer (CRC). The data show that fadraciclib substantially inhibited growth, triggered apoptosis, and induced anaphase catastrophe in CRC patient-derived organoids (PDOs) and xenografts (PDX). The data were presented at a <a href="https://www.globenewswire.com/Tracker?data=DOtUFRdBtrXaK5j-6KOi9X0-hbH0ydRIk4A7NebSXHpepFg5T43Sm2lqcEZaB9MhN78G8X5rZiZF-CqNFKGoPEFhXLhi_bYvWpZ6wbWbacpHcPosIYMjFCZljBkcsdAVTp8kDpjWpncZht2KspSMWrYlEj0jyel-Ba42fDMofB4=">poster</a> at the American Society of Clinical Oncology (ASCO) Annual Meeting from May 31-June 4, 2024 in Chicago, IL.

Cyclacel's Fadraciclib Reports Efficacy In Patient-Derived Colorectal Cancer Models At The 2024 ASCO Annual Meeting

- Clinical, PK and PD data from novel CDK2/9 inhibitor fadraciclib monotherapy studies support ongoing proof of concept study in patients with solid tumors and lymphoma - &nbsp;
BERKELEY HEIGHTS, N.J., June 03, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCC#NASDAQ">CYCC</a>, NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCCP#NASDAQ">CYCCP</a>, ", Cyclacel", or the ", Company", )))), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced that new clinical, pharmacokinetic (PK) and pharmacodynamic (PD) data from the CYC065-101 study of fadraciclib as oral monotherapy was presented at a poster at the American Society of Clinical Oncology (ASCO) Annual Meeting from May 31-June 4, 2024 in Chicago, IL. See link to poster <a href="https://www.globenewswire.com/Tracker?data=rfrkrSM078zh7iszbcFVULyR3lG5tiG0EXp4_KyOnMETwe9v1h1WCv1dTWVsjKgWU9HxZYK4N6yf0oZyJChLR7VVpi5R-SNfqaVYarS-TGnLBad1oxxJRFyzfzZCa0ivJ2cO8emlzfrFzTo29-HMsw==">here</a>.

Cyclacel Pharmaceuticals To Present Clinical Data At 2024 ASCO Annual Meeting Highlighting Oral Fadraciclib's Potential As A Precision Medicine For Cancer

<h3>Gainers</h3>
<ul>
<li>PaxMedica (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PXMD#NASDAQ">PXMD</a>) stock increased by 110.9% to $0.87 during Friday's regular session. The company's market cap stands at $6.4 million. </li>
<li>Q32 Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QTTB#NASDAQ">QTTB</a>) shares rose 23.89% to $29.5. The market value of their outstanding shares is at $351.9 million. </li>
<li>Cyclacel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCCP#NASDAQ">CYCCP</a>) shares increased by 20.45% to $21.2. </li>
<li>SenesTech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNES#NASDAQ">SNES</a>) stock rose 19.95% to $0.89. The market value of their outstanding shares is at $4.5 million. </li>
<li>Rani Therapeutics Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RANI#NASDAQ">RANI</a>) shares moved upwards by 17.48% to $5.25. The market value of their outstanding shares is at $136.7 million. </li>
<li>Allarity Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALLR#NASDAQ">ALLR</a>) shares moved upwards by 16.92% to $2.69. The company's market cap stands at $1.2 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Motus GI Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MOTS#NASDAQ">MOTS</a>) shares declined by 39.0% to $0.26 during Friday's regular session. The company's market cap stands at $1.3 million. </li>
<li>Monogram Orthopaedics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGRM#NASDAQ">MGRM</a>) shares declined by 25.31% to $3.04. The market value of their outstanding shares is at $96.1 million. </li>
<li>BioSig Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BSGM#NASDAQ">BSGM</a>) shares decreased by 20.15% to $1.19. The company's market cap stands at $11.1 million. </li>
<li>Rallybio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RLYB#NASDAQ">RLYB</a>) shares fell 20.14% to $2.38. The market value of their outstanding shares is at $98.6 million. </li>
<li>Portage Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTG#NASDAQ">PRTG</a>) shares fell 18.01% to $0.41. The company's market cap stands at $8.1 million. </li>
<li>Adial Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADIL#NASDAQ">ADIL</a>) stock decreased by 14.1% to $2.56. The market value of their outstanding shares is at $10.3 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ADIL

ALLR

BSGM

MGRM

MOTS

PRTG

PXMD

QTTB

RANI

RLYB

SNES

- New clinical, PK and PD data from novel CDK2/9 inhibitor fadraciclib monotherapy studies support ongoing development program in patients with solid tumors and lymphoma -
BERKELEY HEIGHTS, N.J., April 01, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCC#NASDAQ">CYCC</a>, NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCCP#NASDAQ">CYCCP</a>, ", Cyclacel", or the ", Company", )))), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced that new clinical, pharmacokinetic (PK) and pharmacodynamic (PD) data from the CYC065-101 study of fadraciclib as monotherapy was selected by the Scientific Program Committee for presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting from May 31-June 4, 2024 in Chicago.
Details of the presentations are as follows:
<figure class="table"> 
<table>
<tbody>
<tr>
<td>Title:</td>
<td>A phase 1 study evaluating the safety, pharmacokinetics, and efficacy of fadraciclib, an oral CDK2/9 inhibitor, in patients with advanced solid tumors and lymphoma</td>
</tr>
<tr>
<td>Abstract No.&nbsp;for Publication:</td>
<td>3125</td>
</tr>
<tr>
<td>Session Title:</td>
<td>Poster Session – Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology</td>
</tr>
<tr>
<td>Date and Time:</td>
<td>June 1, 2024, 9:00 AM - 12:00 PM CDT</td>
</tr>
</tbody>
</table>
</figure>
About Cyclin-Dependent Kinases and Fadraciclib Cyclin-dependent kinases (CDKs) are critical for cell cycle control and transcriptional regulation. Dysregulated CDKs have been linked to the cancer hallmarks of uncontrolled proliferation and increased cancer cell survival. Fadraciclib is a highly selective, potent, orally and intravenously available, next generation inhibitor of CDK2 and CDK9. By inhibiting CDK2 and CDK9 fadraciclib causes apoptotic death through anaphase catastrophe of cancer cells at sub-micromolar concentrations.
To date single agent activity, including CR, PR and SD, has been observed in patients with advanced endometrial, squamous NSCLC lung cancer and T-cell lymphoma. Encouraging signals of activity were observed in patients with advanced cervical, hepatocellular, ovarian and pancreatic cancers.
065-101 Study of Oral Fadraciclib
Oral fadraciclib is being tested in a Phase 1/2 trial for the treatment of advanced solid tumors and lymphoma (065-101; <a href="https://www.globenewswire.com/Tracker?data=4O9UTRrc_Lbh9aVJZibg9hr-bEAnUq1rMw_QgFENmv1aR4VmOd1JEAADCHy5GVA57FjhIP8ytpq9VBdOJnh0gqbuqO9sMzavFqHKzgQ4BVFeDjmcfXwqo9-8p4Vvx-pRPDXMe8dCRlkiB7BODij9OeXGV_lyMdGUtKVFjjC0DtM=">NCT#04983810</a>). A total of 47 patients have been treated as monotherapy in this ongoing study. The study is enrolling unselected, all comer patients with advanced solid tumors and lymphoma.
The Phase 2 part of the 065-101 study is designed to further evaluate fadra safety and efficacy in up to 8 cohorts defined by histology and/or NGS. The study is powered to demonstrate response in the molecular subtype suggested by the Phase 1 data and others that may be sensitive.
CDKN2A, CDKN2B deletions
CDKN2A gene deletions occur in over 10% of several solid tumors, including glioma, head and neck, pancreatic, esophageal, lung (incl. squamous), bladder, hepatobiliary, breast, melanoma, sarcoma, and others. In addition, CDKN2A deletions have been reported in 46% of patients with PTCL-NOS, a subtype of lymphoma. CDKN2B deletions occur in over 10% of several solid tumors, including bladder, glioma, lung (incl. squamous), head and neck, pancreatic, melanoma, esophageal, sarcoma, hepatobiliary, breast, ovarian and others.

Cyclacel Pharmaceuticals To Present New Clinical Data At 2024 ASCO Annual Meeting Highlighting Fadraciclib's Potential As A Precision Medicine For Cancer

Cyclacel Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCC#NASDAQ">CYCC</a>, NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCCP#NASDAQ">CYCCP</a>, ", Cyclacel", or the ", Company", )))), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced that preclinical proof-of-concept data with the Company's fadraciclib will be presented at the upcoming <a href="https://www.globenewswire.com/Tracker?data=KURYcXTAECgTx9KiHdZ8eDDE-hid2XQOrxKUfywrqTnWYTFB-bQBL5oYFrgL43p7M1i-0wXWlTJ51idtMMZlvlIlbRaYgMi1gYRRGKZzHt079gRrPSzUQCze3Qc_WhtdGX_Ts8vGPf0LORISopuC7j3Upr87lFsa4FPBQjnpt-UYYPLzdjbLPqS3MfsmLNIDZXo-4itOETODbC_-aYWkjR8onHSb5Xy4-nRIJTD597KzSC7xjx-X-l0z0jD8MddsV_X0as-lMg40jJnVQgH5asw9zo-6CbXSG14lHPXucxvby7KcAzyl6DrXmH7PqqX1TARd6b4OEpgmdFl9UGFnuhTXau8Cu_4xL4TxUd3d4nBfBSVHZcZ9pgVUs89vkIaiSW3x7vabwp27MKeHFw90Lw==">American Association for Cancer Research (AACR) Annual Meeting 2024,</a> being held&nbsp;April 5-10 in&nbsp;San Diego, California. The data will be presented at three poster sessions and report activity and antitumor effects of fadraciclib in biliary tract cancer, lung cancer, Richter transformation and lymphoma cell lines. &nbsp;
Details of the presentations are as follows:
<figure class="table"> 
<table>
<tbody>
<tr>
<td>Title:</td>
<td>The CDK2/9 inhibitor fadraciclib is active in Richter transformation and lymphoma cell lines by targeting both cell survival and proliferation</td>
</tr>
<tr>
<td>Abstract No:</td>
<td>518 / 15</td>
</tr>
<tr>
<td>Session Topic:</td>
<td><a href="https://www.abstractsonline.com/pp8/#!/20272/session/302">Session PO.ET05.01 - Cell Cycle, Transcription Regulation, and Anticancer Drug Action</a></td>
</tr>
<tr>
<td>Date and Time:</td>
<td>April 7, 2024, 1:30 PM - 5:00 PM PT</td>
</tr>
<tr>
<td>Location:</td>
<td>Exhibition Hall, Section 21</td>
</tr>
</tbody>
</table>
</figure>
&nbsp; &nbsp;
<figure class="table"> 
<table>
<tbody>
<tr>
<td>Title:</td>
<td>Elucidation of the fates of CDK2 inhibited aneuploid and residual lung cancers</td>
</tr>
<tr>
<td>Abstract No:</td>
<td>2117 / 8</td>
</tr>
<tr>
<td>Session Topic:</td>
<td><a href="https://www.abstractsonline.com/pp8/#!/20272/session/311">Session PO.ET07.02 - Pharmacodynamic Biomarkers of Drug Response</a></td>
</tr>
<tr>
<td>Date and Time:</td>
<td>April 8, 2024, 9:00 AM - 12:30 PM PT</td>
</tr>
<tr>
<td>Location:</td>
<td>Exhibition Hall, Section 30</td>
</tr>
</tbody>
</table>
</figure>
&nbsp; &nbsp;
<figure class="table"> 
<table>
<tbody>
<tr>
<td>Title:</td>
<td>Anti-tumor effects of fadraciclib, CDK2/9 inhibitor, in biliary tract cancer</td>
</tr>
<tr>
<td>Abstract No:</td>
<td>5711 / 11</td>
</tr>
<tr>
<td>Session Topic:</td>
<td><a href="https://www.abstractsonline.com/pp8/#!/20272/session/360">Session PO.MCB01.01 - Pharmacologic Targeting of Cell Cycle Proteins</a></td>
</tr>
<tr>
<td>Date and Time:</td>
<td>April 9, 2024, 1:30 PM - 5:00 PM PT</td>
</tr>
<tr>
<td>Location:</td>
<td>Exhibition Hall, Section 18</td>
</tr>
</tbody>
</table>
</figure>
About Cyclin-Dependent Kinases and Fadraciclib Cyclin-dependent kinases (CDKs) are critical for cell cycle control and transcriptional regulation. Dysregulated CDKs have been linked to the cancer hallmarks of uncontrolled proliferation and increased cancer cell survival. Fadraciclib is a highly selective, potent, orally and intravenously available, next generation inhibitor of CDK2 and CDK9. By inhibiting CDK2 and CDK9 fadraciclib causes apoptotic death through anaphase catastrophe of cancer cells at sub-micromolar concentrations.
To date single agent activity, including CR, PR and SD, has been observed in patients with advanced endometrial, squamous NSCLC lung cancer and T-cell lymphoma. Encouraging signals of activity were observed in patients with advanced cervical, hepatocellular, ovarian and pancreatic cancers.
065-101 Study of Oral Fadraciclib
Oral fadraciclib is being tested in a Phase 1/2 trial for the treatment of advanced solid tumors and lymphoma (065-101; <a href="https://www.globenewswire.com/Tracker?data=PR_dAy-w0l89F0_hQ5ePrq-9EMTOk5FR9qwOTqAwGpI8rG5aVCTXHAbwHyvK_NSLQ7B5sfMgj047l192PqRfIo-IByZJU7XvkQl1NpqpiWToCITW3ST7xJOGCxM8zrV-qzmefigQs3H7ADZ4qny7ST-hBSW_-cQ3SLv2V6WnEIo=">NCT#04983810</a>). A total of 29 patients have been treated as monotherapy in this ongoing study. The study is enrolling unselected, all comer patients with advanced solid tumors and lymphoma.
The Phase 2 part of the 065-101 study is designed to further evaluate fadra safety and efficacy in up to 8 cohorts defined by histology and/or NGS. The study is powered to demonstrate response in the molecular subtype suggested by the Phase 1 data and others that may be sensitive.
CDKN2A, CDKN2B, MTAP deletions
CDKN2A gene deletions occur in over 40% of several solid tumors, including glioma, head and neck, pancreatic, esophageal, lung (incl. squamous), bladder, melanoma, and others. CDKN2B deletions occur in over 30% of several solid tumors, including bladder, glioma, pancreatic, esophageal, lung (incl. squamous), head and neck, melanoma, and others. MTAP deletions occur in over 25% of several solid tumors, including glioma, mesothelioma, pancreatic, bladder, esophageal and others. MTAP deletion confers dependency on the PRMT5 enzyme in cancer cells which was identified as a synthetic lethal target for MTAP deleted cancers.

Events

Cyclacel Pharmaceuticals Announces Preclinical Proof-Of-Concept Data For Fadraciclib To Be Presented At The American Association For Cancer Research Annual Meeting 2024

Cyclacel Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCC#NASDAQ">CYCC</a>, NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCCP#NASDAQ">CYCCP</a>, ", Cyclacel", or the ", Company", )))), a biopharmaceutical company developing innovative medicines based on cancer cell biology, announced that it received £2.3 million (approximately $2.9 million) as a research &amp; development (R&amp;D) tax credit from HMRC, the tax agency of the United Kingdom government. The tax credit is based on R&amp;D costs incurred in the year ended December 31, 2023. The Company expects to receive an additional approximately $0.8 million following confirmation of a change in the rate of tax credit regarding 2023 expenditures. &nbsp;
"The R&amp;D tax credit has been an important source of non-dilutive capital supporting Cyclacel's programs. We appreciate this governmental support as we evaluate potential precision medicine approaches for both our clinical candidates, oral fadraciclib&nbsp;and oral plogosertib, to address oncology indications with large unmet medical needs," said Paul McBarron, Executive Vice President, Finance &amp; Chief Operating Officer.

Cyclacel Pharmaceuticals Announces Receipt Of $2.9M R&D Tax Credit

<h3>Gainers</h3>
<ul>
<li>Atreca (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCEL#NASDAQ">BCEL</a>) shares increased by 102.7% to $0.22 during Thursday's regular session. The company's market cap stands at $8.6 million. </li>
<li>Sagimet Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMT#NASDAQ">SGMT</a>) stock rose 36.13% to $7.12. The company's market cap stands at $163.0 million. </li>
<li>Cyclerion Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCN#NASDAQ">CYCN</a>) shares increased by 19.89% to $4.4. The market value of their outstanding shares is at $10.7 million. </li>
<li>Galera Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRTX#NASDAQ">GRTX</a>) stock moved upwards by 14.48% to $0.22. The market value of their outstanding shares is at $12.0 million. </li>
<li>Sera Prognostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SERA#NASDAQ">SERA</a>) stock rose 14.45% to $5.78. The company's market cap stands at $181.1 million. </li>
<li>Cyclacel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCCP#NASDAQ">CYCCP</a>) shares increased by 13.12% to $20.25. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>180 Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATNF#NASDAQ">ATNF</a>) shares declined by 26.7% to $0.22 during Thursday's regular session. The market value of their outstanding shares is at $2.2 million. </li>
<li>Cytokinetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYTK#NASDAQ">CYTK</a>) stock declined by 23.15% to $78.11. The company's market cap stands at $7.6 billion. </li>
<li>Evoke Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVOK#NASDAQ">EVOK</a>) shares declined by 20.18% to $0.75. The market value of their outstanding shares is at $2.5 million. </li>
<li>cbdMD (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/YCBD#AMEX">YCBD</a>) shares declined by 16.31% to $0.86. The company's market cap stands at $2.5 million. </li>
<li>Omega Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMGA#NASDAQ">OMGA</a>) stock declined by 14.49% to $4.31. The market value of their outstanding shares is at $237.6 million. </li>
<li>Edgewise Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EWTX#NASDAQ">EWTX</a>) shares declined by 13.06% to $9.66. The market value of their outstanding shares is at $613.0 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ATNF

BCEL

CYCN

CYTK

EVOK

EWTX

GRTX

OMGA

SERA

SGMT

YCBD

12 Health Care Stocks Moving In Thursday's Intraday Session

Cyclacel Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCC#NASDAQ">CYCC</a>, NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCCP#NASDAQ">CYCCP</a>, ", Cyclacel", or the ", Company", )))), a biopharmaceutical company developing innovative medicines based on cancer cell biology, announced today that it has entered into a definitive agreement for the purchase and sale of 388,200 shares of the Company's common stock (or pre-funded warrants in lieu thereof) at a purchase price of $3.315 per share of common stock (or pre-funded warrant in lieu thereof) in a registered direct offering priced at-the-market under Nasdaq rules. The Company will also issue unregistered warrants to purchase up to 388,200 shares of common stock with an exercise price of $3.19 per share which will be immediately exercisable for a period of seven years following issuance. The closing of the offering is expected to occur on or about&nbsp;December 26, 2023, subject to the satisfaction of customary closing conditions. &nbsp;
In a concurrent private placement, the Company will also issue an aggregate of 7,956 shares of common stock at the same purchase price of $3.315 per share and warrants to purchase up to 7,956 shares of common stock with an exercise price of $3.19 per share to members of management.
Ladenburg Thalmann &amp; Co. Inc. is acting as the exclusive placement agent for the offering.

Cyclacel Pharmaceuticals Announces $1.3M Registered Direct Offering Of Of 388,200 Shares At A Price Of $3.315 Per Share And Private Placement Offering Of 7,956 Shares Of Common Stock At A Purchase Price Of $3.315 Per Share

- Patient Pharmacodynamic Data Show Decrease in CDKN2A, CDKN2B, and PRMT5 Protein Levels - 
&nbsp;
- A Squamous Non-Small Cell Lung Cancer Patient with CDKN2B Deletion&nbsp;Achieved Marked Tumor Shrinkage after One Cycle -
- Retrospective Analysis Identified CDKN2A, CDKN2B and/or MTAP Deletions in Four Patients Previously Dosed with Fadra Achieving Responses or Stable Disease -
-&nbsp;Forthcoming Phase 2 Study to Further Evaluate Fadra Efficacy -
BERKELEY HEIGHTS, N.J., Dec. 18, 2023 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCC#NASDAQ">CYCC</a>, NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCCP#NASDAQ">CYCCP</a>, &amp;quot, , Cyclacel&amp;quot, , or the &amp;quot, , Company&amp;quot, , )))), a biopharmaceutical company developing innovative medicines based on cancer cell biology, announced today interim results from its Phase 1, dose escalation 065-101 study of fadraciclib (&quot;fadra&quot;) in patients with advanced solid tumors and lymphoma.
&quot;As we approach the end of the year we are excited to report that fadra continues to demonstrate anticancer activity as a single agent based on interim data reviewed to date from our 065-101 study,&quot; said Spiro Rombotis, President and Chief Executive Officer. &quot;The data suggest tumor sensitivity in patients with one or more of three abnormalities, CDKN2A, CDKN2B and/or MTAP deletion subject to confirmation in further studies. We believe there is great unmet medical need and industry interest in the cancer patient populations identified by these abnormalities, which are closely located on chromosome 9 and are often co-deleted. The Phase 2 part of 065-101 is designed to evaluate fadra safety and efficacy in cohorts defined by histology and/or next generation sequencing (NGS). In addition, our plogosertib dose escalation study is progressing well. Based on interim data reviewed to date, good tolerability and anticancer activity of plogosertib as a single agent have been observed in multiple patients with various solid tumors.&quot;
&quot;We are excited to see shrinkage of&nbsp;22%&nbsp;in the sum of all target lesions after one cycle of fadra monotherapy in a squamous non-small cell lung cancer (NSCLC) patient with CDKN2B deletion refractory to standard of care chemotherapy and immunotherapy,&quot; said Mark Kirschbaum, M.D., Chief Medical Officer. &quot;After retrospectively analyzing a subset of previously treated Phase 1 patients who experienced clinical benefit with fadra, we found four patients with CDKN2A, CDKN2B and/or MTAP deletions. These included an endometrial cancer patient who achieved CR and over three years of treatment in a previous study of fadra monotherapy and was found to have all three abnormalities. Further, pharmacodynamic data from patient biospecimens at dose levels 5 and 6A suggest that CDKN2A, CDKN2B, and PRMT5 protein levels are transiently decreased over the 4 to 8 hour half-life of the fadra dose, which we believe makes the tumor sensitive to CDK2 inhibition by fadra. Although these hypothesis-generating data are limited and cannot be generalized, we believe that patients with these types of tumors should be evaluated in the ongoing and subsequent studies.&quot;
065-101 Study of Oral Fadraciclib
In the ongoing 065-101 study of oral fadra, a CDK2/9 inhibitor, a total of 29 patients have been treated as monotherapy. The study is enrolling unselected, all comer patients with advanced solid tumors and lymphoma. Six patients have been treated on dose level 6A (125mg twice daily for 5 days per week, 4 out of 4 weeks). The sixth patient on dose level 6A with pancreatic cancer and CDKN2A deletion enrolled on the study experienced dose-limiting toxicity (DLT) of hyperglycemia. The patient, who has a diabetic profile history and was on metformin treatment, remains on study as blood glucose level was managed. A previous patient on dose level 6A with a pre-diabetic profile had DLT of hyperglycemia which also resolved rapidly.
The previous dose level 5 (100mg twice daily for 5 days per week, 4 out of 4 weeks) on this schedule accrued six patients with no DLT and per protocol is safe for continued development.
Dose level 6B (150mg once daily for 7 days per week, 4 out of 4 weeks) continues accrual with two patients treated, which are ongoing at three and five cycles of treatment.
To date single agent activity, including CR, PR and SD, has been observed in patients with advanced endometrial, squamous NSCLC lung cancer and T-cell lymphoma. Encouraging signals of activity were observed in patients with advanced cervical, hepatocellular, ovarian and pancreatic cancers.
The Company believes that fadra&#39;s inhibition of CDK2 and CDK9 may be superior to inhibiting either CDK2 or CDK9 alone. Fadra tablets can be given orally with repeat dosing which has led to transient suppression of anti-apoptosis proteins with generally good tolerability and no Grade 3 or higher hematological toxicity in the first cycle.
The Phase 2 part of the 065-101 study is designed to further evaluate fadra safety and efficacy in up to 8 cohorts defined by histology and/or NGS. The study is powered to demonstrate response in the molecular subtype suggested by the Phase 1 data and others that may be sensitive.
CDKN2A, CDKN2B, MTAP deletions
CDKN2A gene deletions occur in over&nbsp;40%&nbsp;of several solid tumors, including glioma, head and neck, pancreatic, esophageal, lung (incl. squamous), bladder, melanoma, and others. CDKN2B deletions occur in over&nbsp;30%&nbsp;of several solid tumors, including bladder, glioma, pancreatic, esophageal, lung (incl. squamous), head and neck, melanoma, and others. MTAP deletions occur in over&nbsp;25%&nbsp;of several solid tumors, including glioma, mesothelioma, pancreatic, bladder, esophageal and others.1&nbsp;MTAP deletion confers dependency on the PRMT5 enzyme in cancer cells which was identified as a synthetic lethal target for MTAP deleted cancers.
140-101 Phase 1 Study of Oral Plogosertib
In the 140-101 study of oral plogosertib, PLK1 inhibitor, as monotherapy, patients are being recruited at dose level 5. The anticancer activity observed at low levels of continuous exposure may be due to plogosertib&#39;s novel epigenetic mechanism.
To date, 15 patients have been recruited at five dose escalation levels. Encouraging signals of activity were observed in five patients with advanced biliary, ovarian, NSCLC and other cancers. The Company expects to announce details of plogosertib&#39;s differentiated, epigenetic mechanism and biomarkers which may identify patients with sensitive tumors, after preclinical studies at collaborating laboratories are completed.

Cyclacel Pharmaceuticals Reports Fadraciclib Phase 1 Data Suggesting Efficacy Against Tumors With CDKN2A, CDKN2B And MTAP Deletions

Cyclacel Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCC#NASDAQ">CYCC</a>, NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCCP#NASDAQ">CYCCP</a>, ", Cyclacel", or the ", Company", )))), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced that it received a notice from&nbsp;The Nasdaq Stock Market LLC&nbsp;("Nasdaq") indicating that the Company has regained compliance with Nasdaq Listing Rule 5250(c)(1) (the "Rule"), by filing its quarterly report on Form 10-Q for the period ended September 30, 2023, on November 29, 2023 with the Securities and Exchange Commission. &nbsp;
Nasdaq Listing Qualifications Department staff has determined that the Company complies with the Rule and advised that the matter is now closed.

Cyclacel Regains Compliance With Nasdaq Listing Rule Following Filing Of Its Form 10-Q With The SEC

<h3>Gainers</h3>
<ul>
<li>Intelligent Bio Solutions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INBS#NASDAQ">INBS</a>) shares increased by 156.6% to $0.58 during Thursday's regular session. Trading volume for this security as of 12:31 EST is 168.8 million, which is 32447.6% of its average full-day volume over the last 100 days. The company's market cap stands at $2.6 million. As per the press release, Q1 earnings came out yesterday. </li>
<li>Tempest Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TPST#NASDAQ">TPST</a>) shares rose 33.32% to $3.76. As of 12:31 EST, Tempest Therapeutics's stock is trading at a volume of 49.6 million, which is 547.9% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $54.7 million. The company's, Q3 earnings came out yesterday. </li>
<li>Lantern Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LTRN#NASDAQ">LTRN</a>) stock moved upwards by 28.12% to $3.59. Trading volume for this security as of 12:31 EST is 276.1K, which is 1068.0% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $38.9 million. As per the press release, Q3 earnings came out yesterday. </li>
<li>Cyclacel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCCP#NASDAQ">CYCCP</a>) stock rose 25.34% to $7.27. </li>
<li>Oncology Institute (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TOI#NASDAQ">TOI</a>) stock rose 23.36% to $2.27. As of 12:31 EST, this security is trading at a volume of 280.0K shares, making up 136.5% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $165.6 million. As per the press release, Q3 earnings came out yesterday. </li>
<li>OncoCyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCX#NASDAQ">OCX</a>) stock rose 20.67% to $2.51. The current volume of 67.1K shares is 505.7% of OncoCyte's average full-day volume over the last 100 days (last updated at 12:31 EST). The company's market cap stands at $20.6 million. As per the news, the Q3 earnings report came out today. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Atara Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATRA#NASDAQ">ATRA</a>) stock decreased by 79.3% to $0.25 during Thursday's regular session. The current volume of 39.3 million shares is 3348.1% of Atara Biotherapeutics's average full-day volume over the last 100 days (last updated at 12:31 EST). The market value of their outstanding shares is at $25.4 million. </li>
<li>Ikena Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IKNA#NASDAQ">IKNA</a>) shares fell 63.69% to $1.5. Trading volume for this security as of 12:31 EST is 1.7 million, which is 1917.2% of its average full-day volume over the last 100 days. The company's market cap stands at $65.7 million. As per the news, the Q3 earnings report came out today. </li>
<li>Acutus Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFIB#NASDAQ">AFIB</a>) stock decreased by 50.8% to $0.23. Acutus Medical's stock is trading at a volume of 1.0 million shares as of 12:31 EST. This is 1095.2% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $6.7 million. As per the news, the Q3 earnings report came out yesterday. </li>
<li>Assertio Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASRT#NASDAQ">ASRT</a>) stock fell 44.84% to $1.18. The current volume of 7.0 million shares is 466.5% of Assertio Holdings's average full-day volume over the last 100 days (last updated at 12:31 EST). The market value of their outstanding shares is at $109.4 million. The company's, Q3 earnings came out yesterday. </li>
<li>Cardio Diagnostics Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDIO#NASDAQ">CDIO</a>) stock declined by 33.09% to $0.92. Trading volume for this security as of 12:31 EST is 14.2 million, which is 163.6% of its average full-day volume over the last 100 days. The company's market cap stands at $17.2 million. </li>
<li>BioVie (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIVI#NASDAQ">BIVI</a>) stock declined by 30.28% to $2.97. The current volume of 776.3K shares is 232.0% of BioVie's average full-day volume over the last 100 days (last updated at 12:31 EST). The company's market cap stands at $109.3 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AFIB

ASRT

ATRA

BIVI

Cardio Diagnostics Holdings Inc. - Common stock

CDIO

IKNA

Intelligent Bio Solutions Inc. - Common Stock

INBS

LTRN

Tempest Therapeutics, Inc. - Common Stock

TPST

Press Releases

Cyclacel Pharmaceuticals Announces Exercise of Warrants for $2.1 Million Gross Proceeds

Financing

Cyclacel Pharmaceuticals Announces Closing of Exercise of Warrants for $2.1 Million Gross Proceeds

Cyclacel Pharmaceuticals Announces Its Exploration of Potential Strategic Alternatives and Reduction of Operating Costs

Cyclacel Pharmaceuticals Announces Agreement for the Acquisition of Preferred Stock by David Lazar

Cyclacel Pharmaceuticals Announces Closing of a Change of Control Transaction and Appointment of New Executive Leadership

Cyclacel Pharmaceuticals Announces $1 Million Private Placement Offering of Convertible Preferred Stock

Earnings

Cyclacel Pharmaceuticals Reports Fourth Quarter Financial Results and Provides Business Update

CYCLACEL PHARMACEUTICALS, INC. ANNOUNCES EXECUTION OF SHARE EXCHANGE AGREEMENT TO MAKE FITTERS SDN. BHD. ITS WHOLLY-OWNED SUBSIDIARY TO ACCELERATE GROWTH AND STOCKHOLDER VALUE

Comments

Cyclacel Pharmaceuticals

空売り

Cyclacel Pharmaceuticals (NASDAQ:CYCCP) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル